 |
 |
Irritable Bowel Syndrome: Getting From Better to Well
Irritable bowel syndrome (IBS) is a highly prevalent and expensive chronic illness associated with significant negative effects on health-related quality of life (HRQoL). The effects of treatment interventions in IBS often are inconsistent,1 and patients and physicians become dissatisfied with therapy.
DECEMBER, 2009 |
|
 |
Management of Irritable Bowel Syndrome: The Importance of Therapy Selection
Irritable bowel syndrome (IBS) is a heterogeneous
disorder that affects 5% to
10% of North Americans and occurs more
often in women than in men. Symptoms
of IBS range in severity and frequency, with abdominal pain and discomfort
and altered bowel habits in the absence
of demonstrable anatomic abnormalities
being the most characteristic.
NOVEMBER, 2009 |
|
 |
The Most Common Sarcomas Arising From the GI Tract
Gastrointestinal stromal tumors (GISTs) are the most common sarcomas arising from the gastrointestinal (GI) tract, with an incidence of 14.5 cases per 1 million individuals. According to the American Cancer Society, there are approximately 4,500 to 6,000 new cases in the United States per year.
NOVEMBER, 2009 |
|
|
|
|
|
 |
The Use of Biologic Therapy in the Treatment of Crohn’s Disease
Significant changes have been made in
the approach to the treatment of inflammatory
bowel disease (IBD) in recent
years. With these advances, the goals of
medical therapy have expanded beyond
inducing and maintaining symptomatic
relief to include averting complications
of the disease.
OCTOBER, 2008 |
|
 |
Assessing Clinical Activity in Crohn’s Disease
Crohn’s Disease (CD) is a complex illness that varies in presentation, anatomic location, clinical course, and response to treatment. Although it is accepted that acute and chronic inflammation contribute to the pathophysiology and symptomatology of CD, the etiology of the disease remains poorly understood. To minimize the effects of CD, clinicians must accurately assess disease activity and tailor therapy according to the many variations in severity, location, extraintestinal manifestations, and perception of disease reported among patients with CD.
AUGUST, 2008 |
|
 |
Management of Patients With Nocturnal GERD
Gastroesophageal reflux disease (GERD) is defined as symptoms or tissue damage that result from reflux of gastric contents into the esophagus. Although approximately 40% of the US population has intermittent symptoms of heartburn at least once per month the prevalence of GERD is 14%.
APRIL, 2008 |
|
1